LCCC 1111: An Open-Label Dose-Finding Study of Lenalidomide as Reinduction/ Consolidation Followed by Lenalidomide Maintenance Therapy for Adults ≥ 60 Years of Age With Acute Myeloid Leukemia (AML) in Partial or Complete Response Following Conventional Induction Therapy

Trial Profile

LCCC 1111: An Open-Label Dose-Finding Study of Lenalidomide as Reinduction/ Consolidation Followed by Lenalidomide Maintenance Therapy for Adults ≥ 60 Years of Age With Acute Myeloid Leukemia (AML) in Partial or Complete Response Following Conventional Induction Therapy

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms LCCC1111
  • Most Recent Events

    • 20 Mar 2018 Planned End Date changed from 1 Apr 2023 to 1 Mar 2022.
    • 20 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 Mar 2017 Planned End Date changed from 1 Feb 2019 to 1 Apr 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top